Jin 2017.

Study characteristics
Methods	RCT, placebo‐controlled trial Date of study: not stated Location: China (number of centres not specified
Participants	Randomised: 18 participants (age median 48 years, 11 male) Inclusion criteria Participants with moderate‐severe psoriasis Authors' assessment > 6 months, PASI ≥ 12, BSA > 10% Age > 18 years Candidates for systemic therapy or phototherapy for psoriasis Exclusion criteria Non‐plaque or drug‐induced psoriasis, or other skin conditions that would interfere with psoriasis evaluation Inability to discontinue current systemic therapy (for at least 4 weeks), topical therapy,or phototherapy (for at least 2 weeks); concomitant oral or injection of corticosteroids; and previous treatment with efalizumab or having participated in studies involving oral tofacitinib Patients were also excluded from the study if they were pregnant or had immune‐deficient diseases or severe systemic disorders Dropouts and withdrawals No statement
Interventions	Intervention A. Tofacitinib (n = 7), orally 10 mg, twice a day, 16 weeks Control intervention B. Tofacitinib (n = 5), orally, 5 mg, twice a day, 16 weeks C. Placebo (n = 6)
Outcomes	Assessments at 16 weeks Outcomes of the trial (not primary ou secondary outcomes) PASI 75 Serum hBD‐2 concentration
Notes	Funding source: Not stated Declarations of interest (p 169): "The authors have no conflict of interest to declare"
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote (supplemental appendix) "The patients were randomized to receive placebo or tofacitinib 5or 10mg twice daily (b.i.d.) for 16 weeks" Comment: no description of the method used to guarantee random sequence generation
Allocation concealment (selection bias)	Unclear risk	Comment: no description of the method used to guarantee random allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote (supplemental appendix) "The patients were randomized to receive placebo or tofacitinib 5or 10mg twice daily (b.i.d.) for 16 weeks" Comment: no more description than using a placebo
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote (supplemental appendix) "The patients were randomized to receive placebo or tofacitinib 5or 10mg twice daily (b.i.d.) for 16 weeks" Comment: no more description than using a placebo
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote (supplemental appendix): "All analyses were intention to treat." No statement on number of missing data and how authors dealt with it
Selective reporting (reporting bias)	Low risk	Comment: no protocol for the study available on ClinicalTrials.gov The prespecified outcomes and those mentioned in the Methods section appeared to have been reported